| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 14.22% | Wells Fargo | $17 → $16 | Maintains | Equal-Weight |
| 11/06/2023 | 21.36% | Wedbush | → $17 | Reiterates | Outperform → Outperform |
| 10/24/2023 | 21.36% | BTIG | → $17 | Upgrades | Neutral → Buy |
| 10/12/2023 | 35.64% | JP Morgan | → $19 | Upgrades | Neutral → Overweight |
| 10/10/2023 | 21.36% | Scotiabank | $19 → $17 | Maintains | Sector Perform |
| 10/06/2023 | 21.36% | BMO Capital | $20 → $17 | Maintains | Market Perform |
| 10/03/2023 | 21.36% | Wedbush | → $17 | Initiates Coverage On | → Outperform |
| 08/22/2023 | 21.36% | Citigroup | $19 → $17 | Maintains | Neutral |
| 08/11/2023 | 71.33% | Barclays | $25 → $24 | Maintains | Equal-Weight |
| 05/11/2023 | 78.47% | Barclays | $24 → $25 | Maintains | Overweight |
| 04/19/2023 | — | Wells Fargo | Initiates Coverage On | → Equal-Weight | |
| 03/29/2023 | 71.33% | Barclays | $28 → $24 | Maintains | Overweight |
| 03/06/2023 | 42.78% | Credit Suisse | $23 → $20 | Downgrades | Outperform → Neutral |
| 12/14/2022 | 42.78% | Citigroup | $22.5 → $20 | Downgrades | Buy → Neutral |
| 12/02/2022 | 57.05% | JP Morgan | $28 → $22 | Maintains | Neutral |
| 09/19/2022 | 99.89% | Citigroup | $27 → $28 | Upgrades | Neutral → Buy |
| 08/11/2022 | 114.16% | SMBC Nikko | → $30 | Upgrades | Neutral → Outperform |
| 07/18/2022 | 107.03% | Credit Suisse | $34 → $29 | Maintains | Outperform |
| 05/10/2022 | 128.44% | Berenberg | $35 → $32 | Downgrades | Buy → Hold |
| 04/26/2022 | 135.58% | Barclays | → $33 | Initiates Coverage On | → Overweight |
| 02/01/2022 | — | Credit Suisse | Initiates Coverage On | → Outperform | |
| 01/07/2022 | 142.72% | BMO Capital | → $34 | Downgrades | Outperform → Market Perform |
| 08/20/2021 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 07/29/2021 | 135.58% | Morgan Stanley | $31 → $33 | Maintains | Equal-Weight |
| 03/31/2021 | 121.3% | Wells Fargo | $29 → $31 | Maintains | Equal-Weight |
| 03/15/2021 | 121.3% | Morgan Stanley | $30 → $31 | Maintains | Equal-Weight |
| 01/28/2021 | 128.44% | Scotiabank | → $32 | Initiates Coverage On | → Sector Perform |
| 01/13/2021 | 135.58% | Jefferies | $30 → $33 | Upgrades | Hold → Buy |
| 09/18/2020 | 135.58% | Capital One | → $33 | Upgrades | Equal-Weight → Overweight |
| 09/02/2020 | 128.44% | Stifel | → $32 | Reinstates | → Buy |
| 08/31/2020 | 149.86% | Raymond James | $34 → $35 | Upgrades | Outperform → Strong Buy |
| 04/29/2020 | 142.72% | Raymond James | $38 → $34 | Maintains | Outperform |
| 04/07/2020 | 107.03% | Citigroup | $38 → $29 | Downgrades | Buy → Neutral |
| 04/03/2020 | 85.61% | Wells Fargo | $33 → $26 | Maintains | Equal-Weight |
| 04/03/2020 | 114.16% | JP Morgan | $35 → $30 | Maintains | Neutral |
| 03/26/2020 | 78.47% | Morgan Stanley | $33 → $25 | Maintains | Equal-Weight |
| 03/12/2020 | 171.28% | Raymond James | $36 → $38 | Maintains | Outperform |
| 03/09/2020 | 206.97% | BMO Capital | $35 → $43 | Upgrades | Market Perform → Outperform |
| 12/20/2019 | 142.72% | Mizuho | → $34 | Assumes | → Neutral |
| 12/12/2019 | — | Citigroup | Upgrades | Neutral → Buy | |
| 11/26/2019 | 149.86% | Stifel | $33 → $35 | Upgrades | Hold → Buy |
| 09/17/2019 | 135.58% | Morgan Stanley | $31 → $33 | Maintains | Equal-Weight |
| 06/20/2019 | 142.72% | Citigroup | → $34 | Initiates Coverage On | → Neutral |
| 01/08/2019 | — | Raymond James | Upgrades | Underperform → Market Perform | |
| 11/13/2018 | 128.44% | Mizuho | → $32 | Upgrades | Neutral → Buy |
What is the target price for Healthcare Realty Trust (HR)?
The latest price target for Healthcare Realty Trust (NYSE: HR) was reported by Wells Fargo on November 13, 2023. The analyst firm set a price target for $16.00 expecting HR to rise to within 12 months (a possible 14.22% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Healthcare Realty Trust (HR)?
The latest analyst rating for Healthcare Realty Trust (NYSE: HR) was provided by Wells Fargo, and Healthcare Realty Trust maintained their equal-weight rating.
When is the next analyst rating going to be posted or updated for Healthcare Realty Trust (HR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Healthcare Realty Trust, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Healthcare Realty Trust was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Healthcare Realty Trust (HR) correct?
While ratings are subjective and will change, the latest Healthcare Realty Trust (HR) rating was a maintained with a price target of $17.00 to $16.00. The current price Healthcare Realty Trust (HR) is trading at is $14.01, which is out of the analyst's predicted range.